In the high-stakes world of advanced therapies, the most critical bottleneck is the factory. For patients waiting on a gene therapy or a personalized cell therapy, the distance between a clinical trial and a vial on the shelf is constrained by a global network of specialized manufacturing plants. National Resilience, known as Resilience, launched in 2020 with a thesis to build a domestic, technology-forward manufacturing network to make these complex medicines at scale [TechCrunch, 2020-11-23].
The manufacturing wedge
Resilience operates as a CDMO, but its differentiation is rooted in scale. Instead of building bespoke facilities, the company assembled a network through acquisitions of existing high-end biologics plants from companies like Sanofi and Amgen [Perplexity Sonar Pro Brief]. This allowed it to offer end-to-end manufacturing for cell therapies, gene therapies, viral vectors, and mRNA vaccines. Its work manufacturing mRNA vaccine substance for Moderna's COVID-19 vaccine provided a proof point for its scaling capabilities [Fierce Pharma].
The company's leadership framed this as a matter of national health security. Resilience raised more than $2 billion in total capital, including equity and debt, to fund its build-out [Stat News].
The team behind the build
The founding coalition brought together venture capital firepower with operational experience. Key architects include Rahul Singhvi (former CEO of Novavax), Robert Nelsen (Arch Venture Partners), Patrick Yang (formerly of Roche/Genentech), and Drew Oetting (8VC) [Forbes, 2021; ARCH Venture Partners, 2026; 8VC]. Singhvi transitioned out in 2024, with William Marth taking over as CEO [Fierce Pharma].
A strategic pivot and consolidation
By mid-2025, the expansion entered a new phase. Resilience announced a strategic restructuring, planning to wind down operations at six facilities across California, Massachusetts, and Florida [BioPharma Dive]. This was accompanied by layoffs at sites in Florida and North Carolina [Endpoints News]. The moves signaled a shift from a land-grab acquisition strategy to a focus on optimizing its network and doubling down on its most strategic sites in the Midwest and Ontario.
Navigating a crowded and capable field
Resilience competes with established giants like Lonza, Samsung Biologics, WuXi Biologics, Catalent, and Thermo Fisher. Resilience's answer rests on three pillars: its North American footprint, its technology investment in next-generation manufacturing, and its founder-level relationships with top-tier biotech VCs.
The patient at the end of the line
Ultimately, the success of Resilience's bet will be measured in patient outcomes. The company is building infrastructure for personalized, living medicines that require exquisite care in manufacturing. Resilience's proposition is to compress and secure that chain within a controlled network. Its recent restructuring may strengthen its ability to deliver on that promise for the specific disease states it chooses to prioritize, from oncology and rare genetic disorders to future pandemic-response vaccines.
The next twelve months will be about proving that the consolidated model works. Key milestones include landing new, flagship partnerships with biotech companies in late-stage clinical trials and achieving consistent operational excellence across its remaining sites.